Published in Ann Intern Med on February 01, 1967
Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect (1999) 1.95
Immunopathologic effects of silicone breast implants. West J Med (1995) 1.39
Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis (1993) 1.30
Eosinophilic fasciitis. Case report and review of the literature. Ann Rheum Dis (1977) 1.23
Epidemiology of scleroderma. Ann Rheum Dis (1991) 1.13
Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology (1998) 1.12
Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol (1997) 1.10
Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med (2002) 1.09
Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ Health (2007) 1.03
What is the contribution of occupational environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis (1992) 1.03
Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health (2010) 1.01
Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med (1981) 1.00
Silica, silicosis, and progressive systemic sclerosis. Br J Ind Med (1985) 0.98
Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res (2011) 0.93
Tryptophan-induced eosinophilia-myalgia syndrome. West J Med (1990) 0.88
Association of pulmonary silicosis and systemic sclerosis. BMJ Case Rep (2015) 0.86
Raised immunoglobulin concentrations in bronchoalveolar lavage fluid of healthy granite workers. Thorax (1986) 0.84
Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses. Ann Rheum Dis (1993) 0.82
Occupational and environmental scleroderma. Systematic review and meta-analysis. Clin Rheumatol (2017) 0.81
Pneumoconiosis and systemic sclerosis following 10 years of exposure to polyvinyl chloride dust. Thorax (1995) 0.76
Systemic sclerosis with hemoptysis and a huge lung cavity. Clin Pract (2011) 0.75
[Silica-associated systemic sclerosis occurring after an occupational exposure to arc welding]. Pan Afr Med J (2016) 0.75
Clinical evaluation of CENP-B and Scl-70 autoantibodies in silicosis patients. Exp Ther Med (2017) 0.75
Epigenetics and systemic sclerosis. Semin Immunopathol (2015) 0.75
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Criteria for the classification of early systemic sclerosis. J Rheumatol (2001) 5.39
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum (1980) 3.87
Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1994) 3.24
Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum (2000) 3.02
Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum (1988) 2.93
Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol (1989) 2.67
Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum (1994) 2.41
Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum (1995) 2.38
Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). Arthritis Rheum (1968) 2.30
Long-term outcomes of scleroderma renal crisis. Ann Intern Med (2000) 2.27
The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum (1997) 2.21
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum (1980) 2.13
Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum (1994) 2.11
Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum (1987) 2.11
Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med (1990) 2.03
Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol (1979) 2.02
Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med (1971) 2.00
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol (1998) 1.97
Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum (2000) 1.97
Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol (1993) 1.96
Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum (1991) 1.94
Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med (1971) 1.93
Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med (1993) 1.91
D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med (1982) 1.84
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum (2000) 1.82
Carpal arthritis with ankylosis in late onset Still's disease. Arthritis Rheum (1976) 1.82
The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum (1997) 1.78
Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum (1995) 1.78
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum (1999) 1.75
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum (1986) 1.72
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis (2006) 1.70
Giant synovial cysts of the calf in patients with rheumatoid arthritis. J Bone Joint Surg Am (1968) 1.62
A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum (1982) 1.62
Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med (1977) 1.57
Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum (1979) 1.57
Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma). J Clin Invest (1976) 1.55
Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum (1988) 1.54
Palmar fasciitis and polyarthritis associated with ovarian carcinoma. Ann Intern Med (1982) 1.51
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum (1982) 1.51
The epidemiology of polymyositis. Am J Med (1970) 1.50
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med (1994) 1.50
Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J Lab Clin Med (1978) 1.47
A brief history of the rheumatic diseases. Bull Rheum Dis (1982) 1.46
Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum (1999) 1.45
Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum (1998) 1.45
Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum (1985) 1.45
Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) (1983) 1.44
Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum (1985) 1.42
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum (2001) 1.42
Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum (1971) 1.40
Photopheresis for scleroderma? No! J Rheumatol (1992) 1.40
Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) (1980) 1.39
D-penicillamine in the treatment of localized scleroderma. Arch Dermatol (1990) 1.39
Effect of food, fast and alcohol on serum uric acid and acute attacks of gout. Am J Med (1967) 1.38
Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol (1990) 1.37
Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum (1984) 1.35
A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol (1990) 1.35
Letter: HL-A antigens in progressive systemic sclerosis (scleroderma). Arthritis Rheum (1975) 1.33
Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum (1992) 1.33
Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum (2001) 1.31
The rheumatic manifestaions of progressive systemic sclerosis (scleroderma). Clin Orthop Relat Res (1968) 1.30
Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum (1984) 1.30
Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med (1987) 1.26
Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med (1984) 1.26
Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med (1984) 1.26
Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis (1973) 1.24
Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum (1992) 1.23
Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am (1990) 1.23
Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome. Ann Neurol (1986) 1.22
Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum (1985) 1.21
Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS, scleroderma). J Lab Clin Med (1981) 1.21
Herpes zoster in systemic lupus erythematosus. J Rheumatol (1995) 1.21
IMPAIRMENT OF URIC ACID EXCRETION IN GOUT. J Clin Invest (1962) 1.18
The early history of antirheumatic drugs. Arthritis Rheum (1970) 1.17
Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum (1968) 1.17
Anemia and scleroderma: frequency, causes, and marrow findings. Arch Intern Med (1968) 1.17
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum (1999) 1.16